{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:31:33Z","timestamp":1792359093427,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Being introduced in 2010, fingolimod was among the first oral therapies for relapsing multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case reports of various cryptococcal infections associated with fingolimod use. To date, approximately 15 such case reports have been published. We present the first and unique case of cryptococcal chest wall mass and rib osteomyelitis associated with fingolimod use. The patient presented with left-side chest pain and was found to have a lower left chest wall mass. Computerized tomography (CT) showed chest wall mass with the destruction of left 7th rib. Aspirate from the mass grew\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    . The isolate was serotype A. Fingolimod was stopped. The patient received liposomal amphotericin B for 2 weeks and started on fluconazole with a plan to continue for 6\u201312 months. The follow-up CT in 6 weeks showed a marked decrease in the size of the chest wall mass. In conclusion, our case highlights the atypical and aggressive form of cryptococcal infection possibly related to immunosuppression from fingolimod use.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2022.942751","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:12:21Z","timestamp":1662549141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Cryptococcal chest wall mass and rib osteomyelitis associated with the use of fingolimod: A case report and literature review"],"prefix":"10.3389","volume":"9","author":[{"given":"Kent","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Etemady-Deylamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Chamberland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Donlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moreira-Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reisenbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getahun","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","article-title":"Sorrell, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fmed.2019.00129","article-title":"Immunomodulatory role of capsular polysaccharides constituents of cryptococcus neoformans","volume":"6","author":"Decote-Ricardo","year":"2019","journal-title":"Front Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.3390\/app12147086","article-title":"Cryptococcus: history, epidemiology, and immune evasion","volume":"12","author":"Diniz-Lima","year":"2022","journal-title":"App Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/s41598-019-43941-w","article-title":"Mortality due to cryptococcus neoformans and cryptococcus gattii in low-income settings: an autopsy study","volume":"9","author":"Hurtado","year":"2019","journal-title":"Sci Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1128\/EC.00162-07","article-title":"Capsule structural heterogeneity and antigenic variation in cryptococcus neoformans","volume":"6","author":"McFadden","year":"2007","journal-title":"Eukaryot Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1038\/srep08008","article-title":"Capsular polysaccharides from cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils","volume":"5","author":"Rocha","year":"2015","journal-title":"Sci Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0065-2164(08)01005-8","article-title":"Virulence in cryptococcus species","volume":"67","author":"Ma","year":"2009","journal-title":"Adv Appl Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2217\/imt.11.86","article-title":"Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy","volume":"3","author":"Vecchiarelli","year":"2011","journal-title":"Immunotherapy."},{"key":"B9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cmi.12067","article-title":"Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen","volume":"15","author":"Johnston","year":"2013","journal-title":"Cell Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/eji.200323848","article-title":"The efficacy of complement-mediated phagocytosis of cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions","volume":"33","author":"Zaragoza","year":"2003","journal-title":"Eur J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-0039-3400280","article-title":"Cryptococcosis","volume":"41","author":"Zavala","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/322597","article-title":"Dismukes, Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy","volume":"33","author":"Pappas","year":"2001","journal-title":"Clin Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12883-020-01741-0","article-title":"Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report","volume":"20","author":"Wienemann","year":"2020","journal-title":"BMC Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.msard.2016.06.007","article-title":"Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis","volume":"9","author":"Ward","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101923","DOI":"10.1016\/j.msard.2019.101923","article-title":"Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: case report and review of published cases","volume":"39","author":"Ma","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clinimag.2018.11.005","article-title":"Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings","volume":"54","author":"Chong","year":"2019","journal-title":"Clin Imaging."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","article-title":"Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod","volume":"72","author":"Achtnichts","year":"2015","journal-title":"JAMA Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/1369378031000137224","article-title":"Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts","volume":"41","author":"Christianson","year":"2003","journal-title":"Med Mycol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e16444","DOI":"10.7759\/cureus.16444","article-title":"primary cutaneous cryptococcosis in a patient on fingolimod: a case report","volume":"13","author":"Dahshan","year":"2021","journal-title":"Cureus."},{"key":"B20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e00810","DOI":"10.1016\/j.idcr.2020.e00810","article-title":"Primary cutaneous cryptococcal infection due to fingolimod - Induced lymphopenia with literature review","volume":"21","author":"Patil","year":"2020","journal-title":"IDCases."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1128\/JCM.01839-06","article-title":"Molecular identification of cryptococcus neoformans serotypes","volume":"45","author":"Enache-Angoulvant","year":"2007","journal-title":"J Clin Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"103675","DOI":"10.1016\/j.msard.2022.103675","article-title":"A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients","volume":"59","author":"Sharma","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"103072","DOI":"10.1016\/j.msard.2021.103072","article-title":"Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis","volume":"53","author":"Cuascut","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00961","DOI":"10.1016\/j.idcr.2020.e00961","article-title":"Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod","volume":"22","author":"Kaur","year":"2020","journal-title":"IDCases."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s10072-020-04728-4","article-title":"Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report","volume":"42","author":"Baghbanian","year":"2021","journal-title":"Neurol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7224\/1537-2073.2018-080","article-title":"Case report: fingolimod and cryptococcosis: collision of immunomodulation with infectious disease","volume":"21","author":"Samudralwar","year":"2019","journal-title":"Int J MS Care."},{"key":"B28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1352458516670732","article-title":"Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?","volume":"23","author":"Carpenter","year":"2017","journal-title":"Mult Scler."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","article-title":"Disseminated Cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod","volume":"55","author":"Seto","year":"2016","journal-title":"Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","article-title":"Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod","volume":"85","year":"2015","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/PAS.0b013e318040ad0a","article-title":"Cryptococcal inflammatory pseudotumors","volume":"31","author":"Sing","year":"2007","journal-title":"Am J Surg Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1172\/JCI136068","article-title":"FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages","volume":"130","author":"Bryan","year":"2020","journal-title":"J Clin Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0258437","DOI":"10.1371\/journal.pone.0258437","article-title":"Spanish, Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: the Spanish GILENYA registry","volume":"16","author":"Meca-Lallana","year":"2021","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2055217318759692","DOI":"10.1177\/2055217318759692","article-title":"Risk factors for fingolimod-induced lymphopenia in multiple sclerosis","volume":"4","author":"Ohtani","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7224\/1537-2073.2019-015","article-title":"Prevalence of latent tuberculosis in the multiple sclerosis clinic and effect of multiple sclerosis treatment on tuberculosis testing","volume":"23","author":"Bouley","year":"2021","journal-title":"Int J MS Care."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Mult Scler."},{"key":"B40","doi-asserted-by":"publisher","first-page":"109635","DOI":"10.1016\/j.mehy.2020.109635","article-title":"Hidden relationship between fingolimod and bleeding: possible novel management of fingolimod-associated lymphopenia","volume":"140","author":"Hanazono","year":"2020","journal-title":"Med Hypotheses."},{"key":"B41","first-page":"53","article-title":"Advantage of Fontana-Masson stain in capsule-deficient cryptococcal infection","volume":"111","author":"Ro","year":"1987","journal-title":"Arch Pathol Lab Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.942751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:12:24Z","timestamp":1662549144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.942751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":41,"alternative-id":["10.3389\/fmed.2022.942751"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.942751","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"article-number":"942751"}}